We are on track for IDE Submission to use RadioGel™ in human clinical trials.
We are on track for IDE Submission to use RadioGel™ in human clinical trials.
IsoPet® is a division of Vivos Inc. dedicated to animal cancer treatment . We have been saving the lives of animals since 2018 and currently have 8 regional clinics across the United States offering IsoPet® as a safer, less invasive cancer treatment for cats, dogs and horses.
Our patented Precision Radionuclide Therapy™ (PRnT) is the future of cancer treatment – the insertion of our radionuclide device directly into the tumor tissue. Vivos Inc. has developed a Yttrium-90 based injectable device to treat tumors in animals (IsoPet® Division) and humans (RadioGel™ Division - currently not approved for human use.)
RadioGel™ is a division of Vivos Inc. dedicated to human cancer treatment that is not currently approved for human use. We are working on our IDE Submission to the FDA to begin clinical trials in humans in the future.